Background and Purpose - Improvement in the National Institutes of Health Stroke Scale (NIHSS) 24 hours after stroke has been associated with subsequent neurological deterioration. We hypothesized that a similar association would be apparent for events occurring after 7 days, when acute changes from edema and herniation are less common. We evaluated the degree of NIHSS improvement at 7 days ( recovery) as a predictor of subsequent neurological deterioration from day 7 to day 90.
Methods - We studied all patients of the Glycine Antagonist (gavestinel) In Neuroprotection ( GAIN) International Trial with ischemic stroke alive at day 7, excluding patients with hemorrhagic events and deaths from nonstroke-related causes. The GAIN International Trial was a randomized, double-blind, placebo-controlled, and parallel-group trial; because the study drug had no effect on stroke outcome, treatment groups were combined for this analysis. Neurological deterioration was assessed by the combined measure, including: ( 1) stroke-related events recorded as "serious adverse events," ( 2) recurrent stroke recorded on a separate case report form, and ( 3) any NIHSS worsening.
Results - Among 1187 patients included, 25% had > 65% recovery. Deterioration was more prevalent in the group with > 65% early recovery (15.5% versus 10.3%; P = 0.01). Logistic regression modeling indicated that recovery was associated with subsequent neurological deterioration ( odds ratio, 1.2; 95% CI, 1.1 to 1.3, per 10% recovery) after adjusting for age, NIHSS at 7 days, and stroke subtype.
Conclusions - Substantial neurological recovery at 7 days is associated with subsequent neurological deterioration.
|Number of pages||6|
|Publication status||Published - Sep 2004|
- cerebral infarction
- disease progression
- recovery of function
- ACUTE ISCHEMIC-STROKE
- RANDOMIZED CONTROLLED-TRIAL
- SHORT-TERM PROGNOSIS
- CEREBRAL INFARCTION
- EARLY RECURRENCE